Nanomedicine For Cancer Diagnosis And Therapy

This book reviews the current applications and future prospects of nanomaterials in cancer diagnostics and therapy. Nanomaterials have recently emerged as a remarkable and promising tool for cancer therapy and diagnosis, due to their broad range of intrinsic molecular properties. To overcome the current limitations of nanoparticles in drug delivery systems, attempts have been made to synthesize nanoparticles from biological materials for targeted cancer therapy. This book provides concise evaluations of various potential bio-inspired platforms that mimic natural components of the body and offer effective and versatile drug delivery systems for cancer therapy. It also assesses the potential of nanoparticles to enhance the outcomes of cancer immunotherapy via immune cell activation and tumor microenvironment modulation. The book also summarizes in the applications of nanomaterials for the detection, prevention, and treatment of solid tumors and in the treatment of leukemia and lymphomas. In closing, it discusses ethical issues in nanomedicine, including risk assessment, risk management, and risk communication during clinical trials. The book offers offers a valuable source of information for students, academics, researchers, scientists, clinicians, and healthcare professionals working in nanotechnology and cancer research.

Advances in Cancer Research, Volume 139, provides invaluable information on the exciting and fast-moving field of cancer research. Original reviews are presented on a variety of topics relating to the rapidly developing intersection between nanotechnology and cancer research, with unique sections in the new release focusing on Exosomes as a theranostic for lung cancer, Nanotechnology and cancer immunotherapy, Ultrasound imaging agents and delivery systems, Dendronized systems for the delivery of chemotherapeutics, Thermosensitive liposomes for image-guided drug delivery, Supramolecular Chemistry in Tumor Analysis and Drug Delivery, Gold nanoparticles for delivery of cancer therapeutics, and Single cell barcode microchip for cancer research and therapy. Provides the latest information on cancer research Offers outstanding and original reviews on a range of cancer research topics Serves as an indispensable reference for researchers and students alike

This Brief focuses on the cancer therapy available till date, from conventional drug delivery to nanomedicine in clinical trial. In addition, it reports on future generation based nanotherapeutics and cancer theranostic agent for effective therapeutic diagnosis and treatment. Breast cancer was chosen as the model system in this review. The authors give emphasis to multiple drug resistance (MDR) and its mechanism and how to overcome it using the nanoparticle approach.

The cancer research world is looking forward to bionanotechnology to find the best solutions for a complete cure from cancer, which is not possible with the current established treatment methods. The past decade of research on nano imaging and drug delivery in cancer has witnessed many interesting papers and reviews, but there has not been a concise resource that discusses all fields related to nano cancer research in diagnosis and drug delivery. This book fills this gap and presents the latest bionano research in cancer, focusing on nanodiagnostics and nanotherapy. The book is organized into two sections. The section on nanodiagnostics focuses on topics such as diagnostic methods in cancer-related therapy and use of radiolabeled nanoparticles, magnetic nanoparticles, acoustically reflective nanoparticles, X-ray computed tomography, and optical nanoprobes for diagnosis. The section on nanotherapy focuses on nanomaterials in chemotherapy, magnetic nanoparticles for hyperthermia against cancer, phototherapy, nanotechnology-mediated radiation therapy, nanoparticle-mediated small-RNA deliveries for molecular therapies, and theranostics. The book will serve as the gateway to enter the beautiful and elegant field of bionanoscience, which is considered the last hope for the fight against cancer and will be a highly useful resource for the students, researchers, teachers, and curious readers working in this field or related fields.

Nanotechnology has revolutionized cancer diagnosis and therapy through targeted drug delivery. Advances in protein engineering and materials science have led to the development of nanocarriers (NCs), which have helped overcome the challenges faced during conventional cancer treatment. These nanocarriers serve as an efficient transport module for drugs. Nano-drug delivery has emerged as a promising technology that results in early detection and better treatment of various cancers. The approved nanoparticles currently used in cancer treatment strategies include liposomes, dendrimers, polyplexes, solid lipid nano-carriers, etc. These nanocarriers can potentially provide a quick, safe, and cost-effective method in cancer therapy and management. This book presents thirteen chapters that cover cancer nanotherapeutics for various cancers. The reference covers lung, breast, cervical, ovarian, colon, prostate, and head and neck cancers. Each chapter reviews advanced data from existing and ongoing clinical research and major regulatory considerations. A list of scientific references for further reading supplements every chapter. Readers will be able to understand recent advances and challenges faced by researchers in cancer nanomedicine. This reference book will greatly benefit undergraduate and postgraduate students, oncologists, pharmacists, and researchers involved in nanomedicine and nano-drug delivery.

Nano Drug Delivery Strategies for the Treatment of Cancers discusses several current and promising approaches for the diagnosis and treatment of cancer by using the most recent developments in nanomedical technologies. The book presents introductory information about the biology of different types of cancer in order to provide the reader with knowledge on their specificities. In addition, it discusses various novel drug delivery systems, detailing their functionalities, expected outcomes and future developments in the field, focusing on brain, mouth and throat, breast, lung, liver, pancreas, stomach, colon, bool, skin and prostate cancers. The book is a valuable source for cancer researchers, oncologists, pharmacologists and nanotechnologists who are interested in novel drug delivery systems and devices for treatment of various types of cancer that take advantage of recent advances in this exciting field. Discusses a wide range of promising approaches for the diagnosis and treatment of cancer using the latest advancement in cutting-edge nanomedical technologies Provides foundational information on different types of cancer and their biology to help the reader choose the best nano drug delivery system for patients Presents novel drug delivery systems based on nanoparticles, microparticles, liposomes, self-assembling Micelles and block copolymer micelles

A meeting report of the 2nd international Else Kr ner-Fresenius Symposium on Nanomedicine Nanomedicine -- the application of nanotechnology to human health -- is a promising field of research at the interface of physical, chemical, biological, and medical science. Recent advances have made it possible to analyze biological systems at cellular and subcellular levels, offering numerous promising approaches to improve medical diagnosis and therapy. It is expected that nanomedicine will have a great impact especially on drug delivery and imaging. In this context, the development of targeted, highly specific nanoparticles is of pivotal importance. The results of these advances will offer personalized diagnostic tools and treatments in the future. Based on the 2nd Else Kr ner-Fresenius-Symposium, this book presents a broad spectrum of topics ranging from nanoscale drug delivery/drug design to nanotoxicity and from diagnostics and imaging to therapeutic applications including antibody therapies. The contributions are authored by leading experts in the field and provide an excellent overview of the current knowledge in nanomedicine. Due to the interdisciplinary nature of the subject area this volume will be of special interest to physicians, biologists, chemists, engineers, and physicists as well as to students in the respective fields.

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.